Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from MorphoSys.

Community Practice Connections™: Bridging Unmet Needs With Emerging Data in Relapsed/Refractory DLBCL to Improve Patient Outcomes

Release Date: January 29, 2021
Expiration Date: January 29, 2022

Activity Overview

Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of cases. The treatment landscape of DLBCL is evolving rapidly, particularly for patients with relapsed/refractory disease, with the recent addition of several new active agents to the armamentarium, and numerous other promising therapies in late-stage clinical development. Further, advances in understanding the underlying biology of DLBCL are resulting in more refined biomarker characterization for enhanced risk assessment and individualization of treatment. Clinicians must be aware of these changes and how to integrate them into their practices in order to optimize outcomes for their patients with DLBCL.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Medical Crossfire® Bridging Unmet Needs With Emerging Data in Relapsed/Refractory DLBCL to Improve Patient Outcomes satellite symposium, held in December 2020. This unique and engaging multi-media activity is directed towards the community-based clinician and focuses on the practical aspects of managing patients with DLBCL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from MorphoSys.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists/hematologists, nurse practitioners, nurses, and fellows who treat patients with DLBCL. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of DLBCL are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine state-of-the-art diagnostic approaches that should be utilized to stratify risk and monitor treatment response in multiple lines of care among patients with DLBCL
  • Describe recent landmark evidence in the setting of relapsed/refractory DLBCL and how new strategies can be practically applied to clinical practices
  • Apply methods to monitor for and mitigate the impact of treatment-related toxicities among patients who are managed for DLBCL
  • Evaluate next steps in the field to address unmet clinical needs in DLBCL management, including recent evidence and ongoing clinical trials evaluating novel approaches in multiple lines of care

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Gilles A. Salles, MD, PhD
Gilles A. Salles, MD, PhD
Lymphoma Service, Chief
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AbbVie, Allogene, Autolus, Beigene, Bristol Myers Squibb/Celgene, Debiopharm, Genmab, Kite/Gilead, Janssen, Milteniy, MorphoSys, Novartis, Roche, VelosBio; Other: Educational events for: AbbVie, Bristol Myers Squibb/Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche.

Ranjana Advani, MD
Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Stanford Cancer Institute
Stanford, CA

Disclosures: Grant Research Support: Agensys, Forty Seven, Inc./Gilead, Janssen Pharmaceutical, Kura, Merck, Millennium, Pharmacyclics, Regeneron, Seattle Genetics; Consultant: Kura, Merck, ADC Therapeutics, Karyopharm, Takeda, Bristol Myers Squibb/Celgene.

Kami J. Maddocks, MD
Kami J. Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The Arthur G. James Cancer Hospital at The Ohio State University
Columbus, OH

Disclosures: No relevant financial relationships with commercial interests to disclose.

Professor Dr. med. Georg Lenz
Professor Dr. med. Georg Lenz
Full Professor
Director, Department of Hematology and Oncology
University Hospital Münster
Münster, Germany

Disclosures: Consultant: Roche, Amgen, Incyte, Bristol Myers Squibb/Celgene, Gilead, Bayer, Novartis, MorphoSys, A&D, AbbVie; Speakers Bureau: Roche, Janssen, Bristol Myers Squibb/Celgene, Gilead, Novartis, MorphoSys, A&D, AbbVie.

Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowski, MD
Associate Professor of Medicine and Oncology
Consultant, Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: MorphoSys, Roche, Bristol Myers Squibb/Celgene; Consultant: MorphoSys, Roche, Bristol Myers Squibb/Celgene, Kite, Denovo, Kymera; Other: MorphoSys, Roche, Bristol Myers Squibb/Celgene, Kite, Denovo, Kymera.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By